Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study

BACKGROUND: Non-small-cell lung cancer (NSCLC) is a global public health problem, and brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy (WBRT) remains a major treatment for brain metastases, while EGFR-tyrosine kinase inhibitor (TKI) is the standard treatment f...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zhi-Yong, Li, Mei-Fang, Lin, Jing-Hui, Lin, Dong, Lin, Ren-Jang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421893/
https://www.ncbi.nlm.nih.gov/pubmed/30936745
http://dx.doi.org/10.2147/CMAR.S184922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421893/
https://www.ncbi.nlm.nih.gov/pubmed/30936745
http://dx.doi.org/10.2147/CMAR.S184922

Ejemplares similares